<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590732</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0183</org_study_id>
    <secondary_id>NCI-2018-01827</secondary_id>
    <secondary_id>2012-0183</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01590732</nct_id>
  </id_info>
  <brief_title>Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma</brief_title>
  <official_title>Phase I Study of Romidepsin (ISTODAXÂ®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose and side effects of romidepsin when given in
      combination with ifosfamide, carboplatin, and etoposide in treating participants with
      peripheral T-cell lymphoma that has come back or does not respond to treatment. Romidepsin
      may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different
      ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
      dividing, or by stopping them from spreading. Giving romidepsin, ifosfamide, carboplatin, and
      etoposide may work better in treating participants with peripheral T-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety profile of romidepsin given before and after ifosfamide, carboplatin,
      etoposide (ICE) chemotherapy for patients with relapsed or refractory peripheral T-cell
      lymphoma (PTCL).

      II. To determine the maximum tolerated dose (MTD), if reached, of romidepsin administered in
      combination with ICE chemotherapy in patients with relapsed or refractory PTCL.

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate (ORR) and complete response (CR) rate in patients
      with relapsed or refractory PTCL.

      OUTLINE: This is a dose-escalation study of romidepsin.

      Participants receive romidepsin intravenously (IV) over 4 hours on days 1 and 4, ifosfamide
      IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours
      on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, participants are followed up within 2-4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2012</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 4 weeks post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 4 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 5.5 years</time_frame>
    <description>Point estimates along with 95% confidence intervals will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Up to 5.5 years</time_frame>
    <description>Point estimates along with 95% confidence intervals will be provided.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Mycosis Fungoides</condition>
  <condition>Recurrent Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>Recurrent Enteropathy-Associated T-Cell Lymphoma</condition>
  <condition>Recurrent Hepatosplenic T-Cell Lymphoma</condition>
  <condition>Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Refractory Anaplastic Large Cell Lymphoma</condition>
  <condition>Refractory Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>Refractory Enteropathy-Associated T-Cell Lymphoma</condition>
  <condition>Refractory Hepatosplenic T-Cell Lymphoma</condition>
  <condition>Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified</condition>
  <arm_group>
    <arm_group_label>Treatment (romidepsin, ifosfamide, carboplatin, etoposide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, ifosfamide, carboplatin, etoposide)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, ifosfamide, carboplatin, etoposide)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, ifosfamide, carboplatin, etoposide)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin, ifosfamide, carboplatin, etoposide)</arm_group_label>
    <other_name>Antibiotic FR 901228</other_name>
    <other_name>Depsipeptide</other_name>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
    <other_name>N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-&gt;1) Lactone, Cyclic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory T cell lymphoma (TCL) status including diagnoses of peripheral
             TCL-not otherwise specified (NOS), angioimmunoblastic TCL, anaplastic large cell
             lymphoma, hepatosplenic TCL, enteropathy-associated TCL, or mycosis
             fungoides(MF)/cutaneous TCL with transformation to systemic TCL

          -  Patients must have received at least one chemotherapy regimen which contained
             doxorubicin

          -  At least one 1.5 cm bidimensional measurable lesion or bone marrow positivity of TCL

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Absolute neutrophil count (ANC) &gt;= 1000 cells/mm3

          -  Platelets &gt;= 80,000 cells/mm3 if baseline bone marrow negative for TCL involvement and
             platelets &gt;= 20,000 cells/mm3 if baseline bone marrow positive for TCL involvement

          -  Bilirubin =&lt; 2 x upper limits of normal (ULN) (Gilbert's =&lt; 3 x upper limit of normal
             [ULN])

          -  Creatinine =&lt; 1.5 x ULN

          -  Alanine aminotransferase (ALT) and aminotransferase (AST) =&lt; 3 x ULN

          -  Negative pregnancy test for females of childbearing potential within 7 days prior to
             start of treatment. Patients of reproductive potential must follow accepted birth
             control methods which include hormonal contraceptive, intra-uterine device, diaphragm
             with spermicide, condom with spermicide, or abstinence during treatment and for 3
             months after completion of treatment

          -  Voluntarily signed Institutional Review Board (IRB) approved informed consent document
             (ICD) before performance of any study-related procedure not part of normal medical
             care, with the understanding that consent may be withdrawn by the subject at any time
             without prejudice to future medical care

        Exclusion Criteria:

          -  History of another malignancy not in remission for at least 2 years (yrs) (except
             non-melanoma skin cancer, stage 0 melanoma, localized prostate cancer, cervical cancer
             in situ)

          -  Known active Central Nervous System (CNS) lymphoma

          -  Ejection fraction (EF) of &lt; 40%, myocardial infarction (MI) within past 3 months,
             uncontrolled angina, severe uncontrolled ventricular arrthymias, or electrocardiogram
             (ECG) evidence of acute ischemia

          -  Grade 3 infection within 2 weeks of first dose romidepsin plus ICE

          -  Pregnant or lactating

          -  Receipt of another investigational drug within 14 days of enrollment

          -  Patients with previous hypersensitivity reactions to the study drugs and components
             (ex: podophyllum and povidone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Fanale</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>September 17, 2018</last_update_submitted>
  <last_update_submitted_qc>September 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

